1. Home
  2. INDP vs MITQ Comparison

INDP vs MITQ Comparison

Compare INDP & MITQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Indaptus Therapeutics Inc.

INDP

Indaptus Therapeutics Inc.

HOLD

Current Price

$2.03

Market Cap

4.7M

Sector

Health Care

ML Signal

HOLD

Logo Moving iMage Technologies Inc.

MITQ

Moving iMage Technologies Inc.

N/A

Current Price

$0.55

Market Cap

5.7M

ML Signal

N/A

Company Overview

Basic Information
Metric
INDP
MITQ
Founded
2000
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Telecommunications Equipment
Sector
Health Care
Telecommunications
Exchange
Nasdaq
Nasdaq
Market Cap
4.7M
5.7M
IPO Year
2021
2019

Fundamental Metrics

Financial Performance
Metric
INDP
MITQ
Price
$2.03
$0.55
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
36.4K
17.7K
Earning Date
05-13-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.01
Revenue
N/A
$20,139,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$56.11
Revenue Growth
N/A
N/A
52 Week Low
$0.27
$0.42
52 Week High
$13.24
$1.66

Technical Indicators

Market Signals
Indicator
INDP
MITQ
Relative Strength Index (RSI) 50.43 44.19
Support Level $1.64 $0.50
Resistance Level $1.99 $0.64
Average True Range (ATR) 0.18 0.04
MACD 0.03 0.00
Stochastic Oscillator 53.33 36.25

Price Performance

Historical Comparison
INDP
MITQ

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.

About MITQ Moving iMage Technologies Inc.

Moving iMage Technologies Inc is engaged in providing designed equipment as well as other off the shelf cinema products needed for contemporary cinema requirements. It offers technical, design and consulting services such as custom engineering, systems design, integration and installation and digital technology, as well as software solutions for operations enhancement and theatre management.

Share on Social Networks: